The p53−/−; Myc hepatoblast cell line were previously developed and characterized as a model to investigate HCC in vitro.22 These cells, marked by p53 loss and Myc overexpression, became immortal in culture and acquired tumorigenic potential, forming liver-derived tumors when injected into nude mice (Supplementary Fig. 1a).22 This cell line exhibits a relatively high IC50 of 8.5 μM for sorafenib, indicating tolerance to drug treatment similar to other sorafenib-resistant HCC cell models reported in the literature (Supplementary Fig. 1b).23 The gene discussed is MYC; the disease is hepatocellular carcinoma.